EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 42 / No 1 (March 2010) J Extra Corpor Technol, 42 1 (2010) 75-79 References
Free Access
Issue
J Extra Corpor Technol
Volume 42, Number 1, March 2010
Page(s) 75 - 79
DOI https://doi.org/10.1051/ject/201042075
Published online 15 March 2010
  1. Ausman RK. Development of a technic for isolated perfusion of the liver. NY State J Med. 1961;61:3993–7. [Google Scholar]
  2. Alexander HRJr, Libutti SK. Isolated hepatic perfusion for extensive liver metastases. London: W.B. Saunders; 2000;81b:1607–15. [Google Scholar]
  3. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;2:176–87. [CrossRef] [PubMed] [Google Scholar]
  4. Didolkar MS, Jackson AJ, Lesko LJ, et al. Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. J Surg Oncol. 1996;3:148–58. [CrossRef] [Google Scholar]
  5. Shiu MH, Knapper WH, Fortner JG, et al. Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). J Clin Oncol. 1986;12:1819–26. [CrossRef] [PubMed] [Google Scholar]
  6. Pontes L, Lopes M, Ribeiro M, Santos JG, Azevedo MC. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Melanoma Res. 1997;5:417–9. [CrossRef] [PubMed] [Google Scholar]
  7. Ariyan S, Poo WJ, Bolognia J. Regional isolated perfusion of extremities for melanoma: A 20-year experience with drugs other than L-phenylalanine mustard. Plast Reconstr Surg. 1997;4:1023–9. [CrossRef] [PubMed] [Google Scholar]
  8. Murdter TE, Linder A, Friedel G, et al. Pharmacokinetics of cyclophosphamide, adriamycin and adriamycin prodrug (HMR 1928) using an ex vivo isolated perfused human lung model (IHLP). Pneumologie. 2000;11:494–8 [in German]. [CrossRef] [PubMed] [Google Scholar]
  9. Burt ME, Liu D, Abolhoda A, et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: A phase I trial. Ann Thorac Surg. 2000;5:1542–9. [CrossRef] [Google Scholar]
  10. Arredondo MA, Chaudhuri B, Kar R, Crist KA, Thomford NR, Chaudhuri PK. Isolated perfusion of pancreas with mitomycin C. Am J Surg. 1990;6:569–74. [CrossRef] [Google Scholar]
  11. Huber R, Kruger I, Kuper K, Huber PM, Pichlmaier H. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. Am J Surg. 1995;4:345–52. [CrossRef] [Google Scholar]
  12. Wile AG, Stemmer EA, Andrews PA, Murphy MP, Abramson IS, Howell SB. Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol. 1985;6:849–52. [CrossRef] [PubMed] [Google Scholar]
  13. Taeger G, Grabellus F, Podleska LE, Muller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008;3:193–203. [CrossRef] [PubMed] [Google Scholar]
  14. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res. 1999;5:491–502. [CrossRef] [PubMed] [Google Scholar]
  15. Tominaga R, Nakano T, Shibata S, et al. Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta. Artif Organs. 2001;1:36–41. [CrossRef] [PubMed] [Google Scholar]
  16. Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R, Fletcher WS. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg. 1988;5:667–71. [CrossRef] [Google Scholar]
  17. Nakayama J, Takeuchi M, Mayumi H, et al. Hyperthermic isolated limb perfusion with intra-arterial administration of carboplatin and/or interferon-beta for the treatment of malignant melanoma of the leg. J Dermatol. 1994;11:915–22. [CrossRef] [Google Scholar]
  18. Zeh HJIII, Brown CK, Holtzman MP, et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2009;16:385–94. [CrossRef] [PubMed] [Google Scholar]
  19. Laubrock N, Hempel G, Schulze-Westhoff P, Wurthwein G, Flege S, Boos J. The stability of doxorubicin and ldarubicin in plasma and whole blood. Chromatographia. 2008;1–2:9–13. [Google Scholar]
  20. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet. 2000;1:1–21. [Google Scholar]
  21. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;4:215–37. [CrossRef] [PubMed] [Google Scholar]
  22. Kosovec JE, Egorin MJ, Gjurich S, Beumer JH. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;2:224–30. [CrossRef] [Google Scholar]
  23. Erkmen K, Egorin MJ, Reyno LM, Morgan RJr, Doroshow JH. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol. 1995;3:254–6. [CrossRef] [PubMed] [Google Scholar]
  24. D’Argenio DZ, Schumitzky A. ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: University of Southern California; 1997. [Google Scholar]
  25. Grover A, Alexander HRJr. The past decade of experience with isolated hepatic perfusion. Oncologist. 2004;6:653–64. [CrossRef] [PubMed] [Google Scholar]
  26. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Clinical Oncology. Philadelphia: Elsevier Churchill Livingstone; 2004:1926. [Google Scholar]
  27. Wanebo HJ, Belliveau JF. A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. Cancer Chemother Pharmacol. 1999;5:427–34. [CrossRef] [PubMed] [Google Scholar]
  28. Aigner K, Walther H, Tonn JC, et al. Isolated liver perfusion with 5-fluorouracil (5-FU) in the human. Chirurg. 1982;9:571–3 [in German]. [Google Scholar]
  29. Beumer JH, Courtney J, Stocker D, et al. Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida, January 2007. Clin Colorectal Cancer. 2007;6:407–22. [CrossRef] [PubMed] [Google Scholar]
  30. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet. 2006;5:357–74. [CrossRef] [Google Scholar]
  31. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;6:567–92. [CrossRef] [PubMed] [Google Scholar]
  32. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;24:5970–6. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.